Jump to content

Next-Gen Cell Line Characterization for Safer, Faster Drug Development

July 23, 2025
Valentina Armiento

In biopharmaceutical development, the integrity of cell lines directly impacts the safety, efficacy, and speed of delivering life-saving therapies. As the foundation for producing monoclonal antibodies, recombinant proteins, gene and cell therapies, and vaccines, cell lines must be rigorously characterized to meet stringent quality standards. Next-generation sequencing (NGS) has emerged as a transformative tool in this process, enabling deeper, faster, and more comprehensive insights into cell line attributes.

To mitigate manufacturing risks, such as contamination or genetic drift, and to accelerate regulatory compliance, it is essential to characterize Critical Quality Attributes (CQAs) such as identity, genetic stability, and purity. Platforms like Genedata Selector® streamline this process by integrating NGS data analysis with regulatory-aligned workflows, helping biopharma teams ensure consistency across batches and sites. Grounded in scientific rigor and international guidelines, cell line characterization not only ensures reliable performance but also builds public trust and drives innovation across the biopharma industry.

What is Cell Line Characterization?

Cell line characterization is the process of thoroughly analyzing cell lines to confirm their identity, stability, and purity. In simple terms, it ensures that the cells used to manufacture biopharmaceuticals are exactly what they should be: free from contaminants, genetically stable, and capable of consistently producing high-quality products. This process plays a critical role in ensuring the safety, efficacy, and purity of biologics and cell-based therapies. By verifying key attributes, such as genetic integrity, absence of adventitious agents, and consistent expression of therapeutic proteins, cell line characterization helps prevent costly manufacturing issues and supports regulatory compliance. Ultimately, it provides confidence that the final drug product is both safe for patients and effective in treating disease.

What is Next-Generation Sequencing?

Next-generation sequencing (NGS) is a high-throughput technology that enables rapid and comprehensive analysis of genetic material. Unlike traditional sequencing methods, which are often time-consuming and limited in scope, NGS can analyze entire genomes or transcriptomes in parallel, delivering deeper insights in a fraction of the time. NGS is especially valuable for cell line characterization in biopharmaceutical development. It allows researchers to detect genetic variations, confirm identity, and assess stability with high sensitivity and accuracy. Compared to conventional in vivo and in vitro assays, NGS provides faster, more detailed results while meeting stringent regulatory requirements. By integrating NGS into cell line development workflows, biopharma teams can accelerate decision-making, reduce risk, and ensure the quality and safety of therapeutic products.

Traditional Cell Line Characterization Methods

Traditional approaches to cell line characterization have relied on a range of assays, each targeting specific quality attributes. These include Short Tandem Repeat (STR) profiling and isoenzyme analysis for confirming identity, mycoplasma and sterility testing for assessing purity, and karyotyping and Southern blot for evaluating genetic stability.1 Phenotypic characterization is also commonly performed, involving assessments of cell morphology, growth behavior, and marker expression (Table 1).

While methods such as PCR and Sanger sequencing have been widely used, they often require multiple assays to achieve a comprehensive view. This fragmented approach can be time-consuming and may still miss low-level contaminants or subtle genomic changes. As biopharmaceuticals become more complex and regulatory expectations increase, these limitations highlight the need for more comprehensive, faster, and more reliable characterization strategies. Ensuring product safety and maintaining regulatory compliance demand tools that can deliver deeper insights with greater efficiency.

Modern Methods in Cell Line Characterization: The Rise in Next-Generation Sequencing

NGS offers a more detailed and comprehensive approach to cell line characterization, replacing or complementing traditional assays. It enables whole genome sequencing for identity, metagenomic sequencing for purity, and copy number variation analysis for stability — all within a single, high-throughput workflow. 

Genedata Selector enhances these NGS-based approaches by managing bioinformatics workflows, tracking samples, and analyzing outcomes with full traceability. It supports regulatory submissions through automated, sample-centric reports and protects IP via secure, in-house analysis. The platform also includes validated Playbooks for common use cases and supports multi-attribute methods (MAM), enabling simultaneous assessment of multiple quality attributes. This streamlines decision-making and ensures consistency across teams and sites. For example, the Genedata Selector MAM Cell Line Characterization Playbook can analyze both short- and long-read NGS data to evaluate the identity of cell line clones, integration sites, the integrity of the relevant genes, and the detection of adventitious agents such as viruses and mycoplasma — all in one run.

Cell line characterization table in Genedata selector
Table 1. NGS applications for cell line characterization.

Clone Selection and Its Role in Cell Line Development

Early clone screening is crucial in cell line development, as it helps identify clones with optimal growth, productivity, and stability.2 This process selects clones with the ideal properties for producing high-quality biopharmaceuticals.3 For monoclonal antibodies and recombinant proteins, it is essential to choose high-yield, genetically stable clones to meet product demands. In gene and cell therapies, clone selection is used to precisely identify the genetic modifications and functional properties of the cell lines. Advanced techniques, such as single-cell cloning, high-throughput screening, and NGS, are employed to select clones that not only meet regulatory requirements but also ensure the efficacy and safety of the final product.

Whole genome sequencing (WGS) with NGS, when combined with sufficient coverage, enables precise detection of genomic integration sites and ensures sequence integrity, thereby accelerating clone selection. However, the data analysis requires significant bioinformatics expertise. Genedata Selector simplifies and accelerates the analysis and management of WGS data. The Integration Site Verification (ISV) Playbook’s step-by-step user guide ensures a smooth analysis process. Automated analysis runs in the background and generates a report upon completion that documents and summarizes all the results and monitors CQAs.

By integrating robust clone selection strategies, biopharmaceutical companies can enhance the reliability and consistency of their manufacturing processes, delivering safer and more effective therapies to patients. Furthermore, establishing cell banks based on the selected clones guarantees that high-quality characteristics are preserved and maintained throughout the production lifecycle.

Ensuring Safe Cell Banks with NGS-Based Testing

The cell banking process starts with the Research Cell Bank, which serves as the basis for creating the Master Cell Bank (MCB). Ensuring that only high-quality, contamination-free cell lines enter the GMP manufacturing step is essential. The MCB undergoes extensive testing for adventitious agents to confirm that the cell lines are free from microbial contaminants such as fungi, bacteria, adventitious viruses, and mycoplasma. The Working Cell Bank (WCB), derived from the MCB, is used for routine production and subject to regular quality control measures. The End-of-Production Cell Bank (EOP CB), sometimes called Post-Production Cell Bank (PPCB), is created from the WCB and undergoes detailed mycoplasma analysis to serve as a reference for future production, ensuring long-term stability and consistency.

Mycoplasma contamination is a critical issue in cell line characterization and development, as it can significantly alter cell physiology and compromise research outcomes. Contamination rates can reach up to 35%, underscoring the importance of regular screening and stringent quality control measures. Implementing advanced detection methods and maintaining rigorous aseptic protocols are essential to ensure the integrity of cell cultures used in research and biopharmaceutical production.4-5 In this context, untargeted NGS analysis can replace targeted PCR-based screening for reliable strain typing. Genedata Selector offers several Playbooks to support NGS-based biosafety assays. Among these, the designated Playbook for Mycoplasma Detection enables users to run the detection assays in a quick, simple, yet robust manner.

Contaminations can originate from raw materials of human or animal origin or be inadvertently introduced during the manufacturing process, necessitating risk assessments to evaluate viral risk factors according to the European Pharmacopoeia Chapter 5.1.7.6 In addition to adventitious agent detection (AAD), the identity and genetic stability of cell lines are extensively tested to ensure that desired characteristics are maintained. The Genedata Selector MAM Cell Line Characterization Playbook enables simultaneous monitoring of these attributes.

Meeting Global Regulatory Requirements for Biopharmaceuticals with Advanced Cell Line Characterization

Establishing a well-characterized cell banking system and selecting optimal clones in a validated environment is essential for ensuring compliance and quality in the manufacturing process within a cGMP setting, as required by global regulators. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has issued two guidelines, ICH Q5B and Q5D, to qualify cell lines. ICH Q5B focuses on analyzing the expression construct in cell lines to ensure genetic stability and integrity,7 while ICH Q5D provides guidance on deriving and characterizing of cell substrates.8 Regulatory authorities also require next-generation characterization of genetic consistency in manufacturing cell lines, performed in accordance with ICH Q5B and Q5D. For eukaryotic expression systems in product license applications, genetic characterization involves verifying the product coding sequence either through nucleic acid testing or by analyzing the final protein product. To enhance genetic characterization capabilities, USP Chapter <1042> recommends using NGS.9

Additional guidelines are provided by the World Health Organization (WHO), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA). These regulations allow scientists to consistently use cell lines and cell banks that maintain genetic stability during long-term storage. This is particularly important for cell and gene therapies, where the precision and stability of cell lines directly impact treatment success. Leveraging this regulatory framework, the Genedata Selector team has extensive expertise in developing tailored solutions for in-house validation of NGS-based assays.

The Future of Cell Line Characterization

As the biopharmaceutical industry continues to evolve, there is a clear shift toward automation, scalability, and data-driven decision-making in cell line characterization. Technologies such as NGS are already transforming how quality attributes are assessed, but the next wave of innovation will be powered by AI and machine learning. These technologies can help predict cell line behavior, identify potential risks earlier, and optimize workflows by learning from historical data. Combined with platforms like Genedata Selector, which already supports automated decision-making and standardized Playbooks, AI-driven tools will further streamline analysis, reduce manual effort, and increase confidence in results. This movement toward intelligent, scalable solutions is essential for keeping pace with growing regulatory demands and the complexity of modern biologics.

Conclusion

Using NGS for cell line characterization offers numerous benefits, including thorough genetic analysis, high accuracy, and faster results. An integrated, in-house platform like Genedata Selector capitalizes upon these advantages by enabling GMP validation within a company’s own facilities. In contrast, attempting to validate NGS-based assays independently is a complex and challenging task, often resulting in fragmented validation efforts. Genedata Selector streamlines this process, providing a unified, comprehensive platform for a series of validated NGS-based assays. This approach ensures compliance with regulatory standards, reduces reliance on external services, increases control over the testing process, and ultimately improves return on investment.

Looking ahead, NGS-MAM is expected to play a crucial role in biopharmaceutical quality control, including cell line characterization. Genedata Selector facilitates global GMP rollouts across institutions of varying sizes. Its scalable and flexible platform can be tailored to meet the specific needs of different organizations, from contract development and manufacturing organizations (CDMOs) and small biotech firms to large pharmaceutical companies. By offering a robust and reliable solution for genetic characterization testing, Genedata Selector streamlines the consistent production of high-quality biopharmaceutical products worldwide, eliminating the need to implement multiple assays to characterize cell lines and ensure patient safety.

The application of NGS in combination with Genedata Selector represents a significant advancement in cell line characterization. These technologies not only increase the accuracy and efficiency of genetic stability testing but also pave the way for future innovations related to the 3Rs (Refine, Reduce, Replace), analytical process automation, and scalability in biopharmaceutical quality control. Embracing these advancements will be key to maintaining the highest standards of product quality and safety in the rapidly evolving biopharmaceutical field.

 

References

  1. Chen, Y.-H.; Connelly, J.; Florian, C.; Cui, X.; Pruett-Miller, S. Short Tandem Repeat Profiling via Next-Generation Sequencing for Cell Line Authentication. Dis Model Mech 2023, 16 (10).
  2. Aeschlimann, S. H.; Graf, C.; Mayilo, D.; Lindecker, H.; Urda, L.; Kappes, N.; Burr, A. L.; Simonis, M.; Splinter, E.; Van Min, M.; Laux, H. Enhanced CHO Clone Screening: Application of Targeted Locus Amplification and Next‐Generation Sequencing Technologies for Cell Line Development. Biotechnol. J. 2019, 14 (7).
  3. Lai, T.; Yang, Y.; Ng, S. K. Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production. Pharmaceuticals (Basel) 2013, 6 (5), 579–603.
  4. Carrillo-Ávila, J. A.; de la Fuente, A.; Aguilar-Quesada, R.; Ligero, G.; Del Río-Ortiz, J. M.; Catalina, P. Development and Evaluation of a New qPCR Assay for the Detection of Mycoplasma in Cell Cultures. Curr. Issues Mol. Biol. 2023, 45 (8), 6903–6915.
  5. Young, L.; Sung, J.; Stacey, G.; Masters, J. R. Detection of Mycoplasma in Cell Cultures. Nat. Protoc. 2010, 5 (5), 929–934.
  6. European Pharmacopoeia. Viral Safety. In Ph. Eur., 6th ed.; EDQM: Strasbourg, France, 2008; Chapter 5.1.7.
  7. International Council for Harmonisation (ICH), European Medicines Agency (EMEA). ICH Topic Q 5 B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cell Lines Used for Production of r-DNA Derived Protein Products; 1996.
  8. International Council for Harmonisation (ICH), European Medicines Agency (EMEA). ICH Topic Q 5 D: Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products; 1998.
  9. United States Pharmacopeia. <1042> Cell Banking Practices for Recombinant Biologics. United States Pharmacopeia–National Formulary (USP–NF); U.S. Pharmacopeial Convention: Rockville, MD, 2023.